Actinogen Medical Limited (ASX:ACW)

Market Cap	168.80M +89.8%
Revenue (ttm)	7.36M -18.4%
Net Income	-17.91M
EPS	-0.01
Shares Out	3.59B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,222,806
Average Volume	3,074,217
Open	0.0470
Previous Close	0.0470
Day's Range	0.0450 - 0.0470
52-Week Range	0.0190 - 0.0720
Beta	0.98
RSI	59.77
Earnings Date	May 26, 2026

About Actinogen Medical

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 6
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ACW

Financial Performance

In fiscal year 2025, Actinogen Medical's revenue was 5.49 million, a decrease of -44.73% compared to the previous year's 9.93 million. Losses were -14.73 million, 12.9% more than in 2024.